Inhibition of P38 Mitogen-activated Protein Kinase and Transforming Growth Factor-beta1/Smad Signaling Pathways Modulates the Development of Fibrosis in Adriamycin-induced Nephropathy

Overview

Journal Am J Pathol

Publisher Elsevier

Specialty Pathology

Date 2006 Oct 31

PMID 17071578

Citations 36

Authors

Jinhua Li

Naomi Vittoria Campanale

Rong Jiao Liang

James Antony Deane

John Frederick Bertram

Sharon Denise Ricardo

Affiliations

Soon will be listed here.

Abstract

Inflammation and fibrogenesis are the two determinants of the progression of renal fibrosis, the common pathway leading to end-stage renal disease. The p38 mitogen-activated protein kinase (MAPK) and transforming growth factor (TGF)-beta1/Smad signaling pathways play critical roles in inflammation and fibrogenesis, respectively. The present study examined the beneficial renoprotective effect of combination therapy using the p38 MAPK pathway inhibitor (SB203580) and a TGF-beta receptor I (ALK5) inhibitor (ALK5I) in a mouse model of adriamycin (ADR) nephrosis. The p38 MAPK and TGF-beta1/Smad2 signaling pathways were activated in ADR-induced nephropathy in a sequential time course manner. Two weeks after ADR injection, the combined administration of SB203580 (1 mg/kg/24 hours) and ALK5I (1 mg/kg/24 hours) markedly reduced p38 MAPK and Smad2 activities. Moreover, the co-administration of SB203580 and ALK5I to ADR-injected mice resulted in a down-regulation of total and active TGF-beta1 production, reduced myofibroblast accumulation, and decreased expression of collagen type IV and fibronectin. In these mice, retardation in the development of glomerulosclerosis and interstitial fibrosis was observed. In conclusion, although p38 MAPK and TGF-beta1/Smad signaling pathways are distinct they coordinate the progression of renal fibrosis in ADR nephrosis. The co-administration of a p38 MAPK inhibitor and an ALK5 inhibitor may have potential applications in the treatment of renal fibrosis.

Citing Articles

Pathogenesis of Focal Segmental Glomerulosclerosis and Related Disorders.

Altintas M, Agarwal S, Sudhini Y, Zhu K, Wei C, Reiser J Annu Rev Pathol. 2025; 20(1):329-353.

PMID: 39854184 PMC: 11875227. DOI: 10.1146/annurev-pathol-051220-092001.

PIK-III exerts anti-fibrotic effects in activated fibroblasts by regulating p38 activation.

Sanchez S, McDowell-Sanchez A, Al-Meerani S, Cala-Garcia J, Waich Cohen A, Ochsner S PLoS One. 2024; 19(9):e0306624.

PMID: 39240940 PMC: 11379285. DOI: 10.1371/journal.pone.0306624.

Resveratrol treatment ameliorates hepatic damage via the TGF-β/SMAD signaling pathway in a phenobarbital/CCl-induced hepatic fibrosis model.

Aykac M, Balkan E, Gedi Kli S, Ozturk N Iran J Basic Med Sci. 2024; 27(9):1124-1133.

PMID: 39055873 PMC: 11266736. DOI: 10.22038/IJBMS.2024.75737.16398.

Alantolactone Attenuates Renal Fibrosis via Inhibition of Transforming Growth Factor β/Smad3 Signaling Pathway.

Lee K, Hwang Y, Jung G Diabetes Metab J. 2024; 48(1):72-82.

PMID: 38173367 PMC: 10850280. DOI: 10.4093/dmj.2022.0231.

Salvianolic Acid A Improves Rat Kidney Injury by Regulating MAPKs and TGF-β1/Smads Signaling Pathways.

Diao H, Zhu W, Liu J, Yin S, Wang J, Li C Molecules. 2023; 28(8).

PMID: 37110864 PMC: 10144349. DOI: 10.3390/molecules28083630.

References

Han J, Lee J, Bibbs L, Ulevitch R . A MAP kinase targeted by endotoxin and hyperosmolarity in mammalian cells. Science. 1994; 265(5173):808-11. DOI: 10.1126/science.7914033. View

Zhang G, Moorhead P, El Nahas A . Myofibroblasts and the progression of experimental glomerulonephritis. Exp Nephrol. 1995; 3(5):308-18. View

Stambe C, Nikolic-Paterson D, Hill P, Dowling J, Atkins R . p38 Mitogen-activated protein kinase activation and cell localization in human glomerulonephritis: correlation with renal injury. J Am Soc Nephrol. 2004; 15(2):326-36. DOI: 10.1097/01.asn.0000108520.63445.e0. View

Fukasawa H, Yamamoto T, Suzuki H, Togawa A, Ohashi N, Fujigaki Y . Treatment with anti-TGF-beta antibody ameliorates chronic progressive nephritis by inhibiting Smad/TGF-beta signaling. Kidney Int. 2003; 65(1):63-74. DOI: 10.1111/j.1523-1755.2004.00393.x. View

Wang Y, Wang Y, Tay Y, Harris D . Progressive adriamycin nephropathy in mice: sequence of histologic and immunohistochemical events. Kidney Int. 2000; 58(4):1797-804. DOI: 10.1046/j.1523-1755.2000.00342.x. View

Grygielko E, Martin W, Tweed C, Thornton P, Harling J, Brooks D . Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-beta type I receptor kinase in puromycin-induced nephritis. J Pharmacol Exp Ther. 2005; 313(3):943-51. DOI: 10.1124/jpet.104.082099. View

Tsukada S, Westwick J, Ikejima K, Sato N, Rippe R . SMAD and p38 MAPK signaling pathways independently regulate alpha1(I) collagen gene expression in unstimulated and transforming growth factor-beta-stimulated hepatic stellate cells. J Biol Chem. 2005; 280(11):10055-64. DOI: 10.1074/jbc.M409381200. View

Rodriguez-Vita J, Sanchez-Lopez E, Esteban V, Ruperez M, Egido J, Ruiz-Ortega M . Angiotensin II activates the Smad pathway in vascular smooth muscle cells by a transforming growth factor-beta-independent mechanism. Circulation. 2005; 111(19):2509-17. DOI: 10.1161/01.CIR.0000165133.84978.E2. View

Lee J, Kassis S, Kumar S, Badger A, Adams J . p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. Pharmacol Ther. 1999; 82(2-3):389-97. DOI: 10.1016/s0163-7258(99)00008-x. View

10.

Border W, Noble N . TGF-beta in kidney fibrosis: a target for gene therapy. Kidney Int. 1997; 51(5):1388-96. DOI: 10.1038/ki.1997.190. View

11.

Noronha I, Fujihara C, Zatz R . The inflammatory component in progressive renal disease--are interventions possible?. Nephrol Dial Transplant. 2002; 17(3):363-8. DOI: 10.1093/ndt/17.3.363. View

12.

Yoshinari D, Takeyoshi I, Koibuchi Y, Matsumoto K, Kawashima Y, Koyama T . Effects of a dual inhibitor of tumor necrosis factor-alpha and interleukin-1 on lipopolysaccharide-induced lung injury in rats: involvement of the p38 mitogen-activated protein kinase pathway. Crit Care Med. 2001; 29(3):628-34. DOI: 10.1097/00003246-200103000-00029. View

13.

Isaka Y, Fujiwara Y, Ueda N, Kaneda Y, Kamada T, Imai E . Glomerulosclerosis induced by in vivo transfection of transforming growth factor-beta or platelet-derived growth factor gene into the rat kidney. J Clin Invest. 1993; 92(6):2597-601. PMC: 288455. DOI: 10.1172/JCI116874. View

14.

Ono K, Han J . The p38 signal transduction pathway: activation and function. Cell Signal. 2000; 12(1):1-13. DOI: 10.1016/s0898-6568(99)00071-6. View

15.

Vleming L, Baelde J, Westendorp R, Daha M, van Es L, Bruijn J . The glomerular deposition of PAS positive material correlates with renal function in human kidney diseases. Clin Nephrol. 1997; 47(3):158-67. View

16.

Border W, Okuda S, Languino L, Sporn M, Ruoslahti E . Suppression of experimental glomerulonephritis by antiserum against transforming growth factor beta 1. Nature. 1990; 346(6282):371-4. DOI: 10.1038/346371a0. View

17.

Hommes D, van den Blink B, Plasse T, Bartelsman J, Xu C, Macpherson B . Inhibition of stress-activated MAP kinases induces clinical improvement in moderate to severe Crohn's disease. Gastroenterology. 2002; 122(1):7-14. DOI: 10.1053/gast.2002.30770. View

18.

Furuichi K, Wada T, Iwata Y, Sakai N, Yoshimoto K, Mukaida N . Administration of FR167653, a new anti-inflammatory compound, prevents renal ischaemia/reperfusion injury in mice. Nephrol Dial Transplant. 2002; 17(3):399-407. DOI: 10.1093/ndt/17.3.399. View

19.

Stambe C, Atkins R, Tesch G, Masaki T, Schreiner G, Nikolic-Paterson D . The role of p38alpha mitogen-activated protein kinase activation in renal fibrosis. J Am Soc Nephrol. 2004; 15(2):370-9. DOI: 10.1097/01.asn.0000109669.23650.56. View

20.

Badger A, Bradbeer J, Votta B, Lee J, Adams J, Griswold D . Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. J Pharmacol Exp Ther. 1996; 279(3):1453-61. View